Parkinson’s disease in patients with Gaucher’s disease – causation or association?
Objective: To do a systematic review to find the risk of Parkinson's disease in patients with Gaucher’s disease. Background: Parkinson's disease (PD) is the second…TREM2 maintain microglial proliferation and α-syn accumulation in PD models via the PI3K-Akt pathway
Objective: To investigate the effect and role of TREM2 in microglial proliferation, α-syn-associated pathology and dopaminergic degeneration in Parkinson’s disease (PD). Background: PD is characterised…Anle138b-P1-02: A randomised, double-blinded, placebo-controlled phase 1b study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of the oligomer modulator anle138b in Parkinson´s disease
Objective: To present first-in-patient data of the oligomer modulator anle138b (TEV-56286, emrusolmin) in patients with Parkinson’s disease (PD). Background: Synucleinopathies such as PD and Multiple…Impaired lysophagy function exacerbates propagation of α-synuclein aggregation
Objective: We aimed to clarify how exogenous αSyn aggregates interact with native αSyn in the cytoplasm and seed aggregation, and what defense mechanisms protect against…Pathological findings in a case of DJ-1 early onset Parkinson’s disease
Objective: To report the postmortem findings in a case of early onset genetically confirmed DJ-1 (PARK7) PD. Background: As a very rare cause (1-2%) of…Glunomab: a novel therapeutics for the treatment of Parkinson’s Disease
Objective: The focus of this study was: 1) to characterize the expression and the localization of an endogenous protease, tissue plasminogen activator (tPA) in the…Evaluation of small extracellular vesicles derived miRNA as biomarkers for Parkinson’s disease: comparison with plasma miRNA
Objective: To identify differentially expressed small extracellular vesicles (sEV) derived miRNAs in Parkinson’s disease using small RNA-sequencing and to evaluate their potential as biomarker targets.…IP-RT-QuIC Identify Disease-Specific Alpha-Synuclein Seeds in serum from patients with syncleinopathy
Objective: To examine whether alpha-synuclein (aSyn) seed exists in the serum and its potential as a serum biomarker. Background: Parkinson’s disease (PD) and Multiple system…Glucocerebrosidase (GCase) activator, Ambroxol, reduces alpha-synuclein serine-129 phosphorylation and oligomers in mutant LRRK2 R1441G mouse brains
Objective: To explore whether inducing brain GCase activity by Ambroxol™ (ABX; a brain-penetrant GCase activator) can reduce a-synuclein (αSyn) serine-129 phosphorylation and oligomer accumulation in…Lysosomal-driven reduction of alpha-synuclein aggregates in a neuron-like model of Parkinson’s disease
Objective: To test whether PIKfyve inhibition results in a lysosomal-driven reduction of alpha-synuclein aggregates in a mutant neuroblastoma cell line overexpressing an aggregation-prone form of…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 60
- Next Page »